Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-CLS-579 |
Synonyms | |
Therapy Description |
ABBV-CLS-579 inhibits PTPN2 and PTPN1, which potentially leads to antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT257). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-CLS-579 | ABBV-CLS579|ABBV-CLS 579|ABBV 579 | ABBV-CLS-579 inhibits PTPN2 and PTPN1, which potentially leads to antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT257). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04417465 | Phase I | ABBV-CLS-579 ABBV-CLS-579 + unspecified PD-1 antibody | First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors | Active, not recruiting | USA | ISR | FRA | ESP | 3 |